A biotechnology company focused on developing small‑molecule therapies for cancer and immune‑mediated diseases, best known for the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, marketed as Imbruvica for several B‑cell malignancies. The drug’s commercial success and partnership with Johnson & J...
1 member of Congress has disclosed 1 trade in 122846 (PCYC), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2024-03-15 | Thomas R Carper | buy | $1K – $15K |